Journal of Pharmacology and Experimental Therapeutics
April 8, 2011
Michael B. Gatch, Michael J. Forster, Aaron Janowsky et al.
42 citations
The abuse liability profile of three synthetic hallucinogens, N,N-diisopropyltryptamine (DIPT), 5-N,N-diethyl-5-methoxytryptamine (5-MeO-DET), and 5-methoxy-α-methyltryptamine (5-MeO-AMT), was tested in rats trained to discriminate hallucinogenic and psychostimulant compounds, including cocaine, methamphetamine, 3,4-methylenedioxymethylamphetamine (MDMA), lysergic acid diethylamide (LSD),...
Current Neuropharmacology
March 1, 2011
Chiharu Sogawa, Norio Sogawa, Kazumi Ohyama et al.
50 citations
Methylone (2-methylamino-1-[3,4-methylenedioxyphenyl]propane-1-one) is a synthetic hallucinogenic amphetamine analog, like MDMA (3,4-methylenedioxy- methamphetamine), considered to act on monoaminergic systems. However, the psychopharmacological profile of its cytotoxicity as a consequence of monoaminergic deficits remains unclear. We examined here the effects of methylone on the transporters...
PLoS One
December 2, 2010
Gantt P. Galloway, Jennifer D. Siegrist, Lynn C. Robertson et al.
22 citations
BACKGROUND: The mechanisms of drug-induced visions are poorly understood. Very few serotonergic hallucinogens have been studied in humans in decades, despite widespread use of these drugs and potential relevance of their mechanisms to hallucinations occurring in psychiatric and neurological disorders. METHODOLOGY/PRINCIPAL FINDINGS: We investigated the mechanisms of hallucinogen-induced visions...
Addiction Biology
November 11, 2010
Jillian H. Broadbear, Brendan J. Tunstall, Katherine Beringer
38 citations
ABSTRACT 3,4‐Methylenedioxymethamphetamine (MDMA, ‘ecstasy’) use results in distinctive mood changes of a prosocial nature, most likely through its enhancement of serotonin (5HT) neurotransmission. Activation of 5HT‐1A postsynaptic receptors has been shown to stimulate the release of oxytocin in the central nervous system where it regulates aspects of mood and behavior. Using a drug...
Journal of Pharmacology and Experimental Therapeutics
July 16, 2010
Bethann N. Johnson, Bryan K. Yamamoto
22 citations
Stress facilitates drug abuse by humans. In rodents, stress enhances the neurochemical, neuroendocrine, and behavioral responses to psychostimulants. Although chronic unpredictable stress (CUS) enhances the acute hyperthermic and long-term monoamine-depleting effects of the psychostimulant +3,4-methylenedioxymethamphetamine (MDMA), the roles of hyperthermia and corticosterone (CORT) in...
Revista Brasileira de Farmacognosia
July 1, 2010
Thiago Berti Kirsten, Maria Martha Bernardi
7 citations
Psilocybe cubensis (Ear.) Sing., Strophariaceae, is a hallucinogen mushroom that has been used since the old times by humans, causing several psychotic effects. P. cubensis contains two tryptamine derivates: psilocybin and psilocin, agonists of the 5-HT2 receptor (serotonin). The main objective of this study was to investigate the acute toxicity effects of P. cubensis aqueous extract (PCAE)...
Current Pharmaceutical Biotechnology
June 27, 2010
Emanuela Turillazzi, Irene Riezzo, Margherita Neri et al.
43 citations
Studies conducted in humans or in animals explored the presence, nature and potential causes of 3,4-methylenedioxymethamphetamine (MDMA) toxicity. According to literature, there are four principal types of such serious toxicity: hepatic, cardiovascular, cerebral and hyperpyrexic. The molecular mechanisms involved in the genesis of these toxic effects are not yet fully clarified, but the...
Current Pharmaceutical Biotechnology
June 27, 2010
Sumit Sarkar, Larry Schmued
63 citations
"Ecstasy" (MDMA) is a powerful hallucinogenic drug which has raised concern worldwide because of its high abuse liability. A plethora of studies have demonstrated that MDMA has the potential to induce neurotoxicity both in human and laboratory animals. Although research on MDMA has been carried out by many different laboratories, the mechanism underlying MDMA induced toxicity has not been fully...
Journal of Neurochemistry
January 12, 2010
Elisa Torres, María Dolores Gutiérrez‐lópez, Érika Borcel et al.
44 citations
J. Neurochem. (2010) 10.1111/j.1471‐4159.2010.06578.x Abstract 3,4‐Methylenedioxymethamphetamine (MDMA, ‘ecstasy’) produces selective long‐lasting serotonergic neurotoxicity in rats. The drug also produces acute hyperthermia which modulates the severity of the neurotoxic response. In addition, MDMA produces signs of neuroinflammation reflected as microglial activation and an increase in the...
Behavioral Neuroscience
October 1, 2009
Jacobi I. Cunningham, Jamie Raudensky, John Tonkiss et al.
27 citations
3,4-Methylenedioxymethamphetamine (MDMA) is a drug of abuse worldwide and a selective serotonin (5-HT) neurotoxin. An important factor in the risk of drug abuse and relapse is stress. Although multiple parallels exist between MDMA abuse and stress, including effects on 5-HTergic neurotransmission, few studies have investigated the consequences of combined exposure to MDMA and chronic stress....